Allergan

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland.

Allergan Plc (AGN) CEO Brent Saunders on Q1 2019 Results - Earnings Call Transcript

Allergan Plc Chief Executive Brent Saunders said on Tuesday that he and the board of directors were looking with a sense of urgency at all options to revive the Botox maker's falling share price, but a lack of specifics failed to boost investor sentiment.

Allergan CEO says company is urgently looking at all options to boost share price

Allergan's (AGN) stock declines slightly in pre-market trading despite the company delivering earnings and revenue beat in the first quarter while marginally raising its guidance

Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View

Mylan

Allergan and Mylan earnings beat first-quarter estimates Tuesday, but Mylan stock tumbled after sales came in light.

Allergan, Mylan Top Earnings Views, But Mylan Dives On Sales Lag

Allergan (AGN) delivered earnings and revenue surprises of 6.76% and 2.04%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Allergan (AGN) Q1 Earnings and Revenues Top Estimates

Shares of Allergan Plc AGN, +1.34% fell 0.5% in premarket trade Tuesday after the company reported earnings and revenue that beat expectations, while boosting its full-year outlook.

Allergan stock down 0.5% despite earnings and revenue beat

Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Allergan (AGN)

Heading into earnings, shares of the pharma company are positioned for a big move, with technical signals pointing to a move lower.

Allergan Stock Could Break Below Wedge Pattern

Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales

Can Allergan (AGN) Beat Earnings Estimates Again in Q1?

Allergan (AGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Allergan (AGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

On Monday, a pair of proxy advisory firms backed Allergan's decision to allow Chief Executive Brent Saunders to also retain his chairman position. Shareholders are set to vote on May 1.

Allergan Snags Key Endorsement For Brent Saunders To Remain CEO, Chair

Macy's

CVS Health

Good bargains are hard to find in today's market. We have a few overlooked stocks for you to capitalize on.

3 Value Stocks Are Absurdly Cheap Right Now

Conatus Pharma

Gilead Sciences

Intercept Pharma

Merck

Novartis

NASH is a highly lucrative market with blockbuster potential. Let us take a look at the winners and losers in this space so far in 2019.

NASH Scorecard So Far This Year: A Look at the Hits & Misses

Liver Therapy Forum weekly digest provides an overview on what’s happening in the NASH landscape in 2019.

Allergan In NASH, And The Market Assessment

Johnson & Johnson

SAGE Therapeutics

Recent activity in depression treatment from Johnson & Johnson and Allergan could benefit Sage Therapeutics, an analyst said Thursday.

Why News From J&J, Allergan Could Be A Boon For This Biotech Stock

Allergan plc (AGN) was in for a disappointment with its investigational depression drug candidate Rapastinel, one day after Johnson & Johnson secured FDA approval for its treatment-resistant depression drug esketamine.

News for Allergan Stock (AGN)